FundingWatcher
Home / Startups / By venture fund / Bristol-Myers Squibb portfolio companies

Bristol-Myers Squibb portfolio companies

Updated 16 Nov 2026

http://www.bms.com

Bristol-Myers Squibb portfolio companies
One-time CSV
  • 20 funded companies, 20 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-investor-bristol-myers-squibb.csv20 rows × 18 columns
CompanyCityLast roundAmountDate
Ratio TherapeuticsBostonSeries C$70.0M2026-07-31
BigHat BiosciencesSan MateoSeries C$75.0M2026-09-24
Precede BiosciencesBostonSeries B$63.5M2026-01-12
Capstan TherapeuticsSan DiegoSeries B$175.0M2024-03-20
GlycoEraWädenswilSeries B$130.0M2025-05-27
ROME TherapeuticsCambridgeSeries B$72.0M2023-09-12
TORL BioTherapeuticsCulver CitySeries C$96.0M2025-10-07
Cour Pharmaceuticals DevelopmentSkokieSeries B$50.0M2026-06-18

8 rows of the CSV in 5 of its 18 columns.

20
Startups
$4.1B
Total raised
4
Funded in the last 12 months
$258.5M
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

15 of 20
15 rows
Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
BigHat Biosciences BigHat Biosciences develops antibody and protein therapeutics using machine learning and automated experimentation. Artificial intelligence San Mateo, United States Series C $75.0M 2026-09-24 $174.3M Andreessen Horowitz, Gaingels, 8VC +2 51 to 100 2019
Ratio Therapeutics Ratio Therapeutics develops radiopharmaceuticals to treat solid tumors in clinical trials. Biotech Boston, United States Series C $70.0M 2026-07-31 $160.0M Bristol-Myers Squibb, The Pags Group, Schusterman Family Investments 11 to 50 2021
Cour Pharmaceuticals Development Cour Pharmaceuticals Development develops nanoparticle technology to reset immune systems in multiple sclerosis patients. Biotech Skokie, United States Series B $50.0M 2026-06-18 $185.5M Alpha Wave Global, Bristol-Myers Squibb, Alpha Wave Ventures +2 51 to 100 2015
Precede Biosciences Precede Biosciences develops blood-based tests that reveal disease-defining transcriptional biology. Biotech Boston, United States Series B $63.5M 2026-01-12 $140.5M Bristol-Myers Squibb, Lilly Asia Ventures, 5AM Ventures +2 11 to 50 2005
TORL BioTherapeutics TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing new therapies. Biotech Culver City, United States Series C $96.0M 2025-10-07 $412.0M Goldman Sachs, RA Capital Management, Alexandria Venture Investments +2 51 to 100 2018
GlycoEra GlycoEra researches and produces extracellular protein degraders for treating autoimmune diseases. Biotech Wädenswil, Switzerland Series B $130.0M 2025-05-27 $179.3M Sofinnova Partners, Bristol-Myers Squibb, 5AM Ventures +1 11 to 50 2020
ArsenalBio ArsenalBio develops programmable CAR T-cell therapies for solid tumors. Biotech South San Francisco, United States Series C $325.0M 2024-09-04 $630.8M ARCH Venture Partners, Bristol-Myers Squibb, NVentures +1 251 to 500 2019
Autobahn Therapeutics Autobahn Therapeutics develops restorative treatments for neuropsychiatric and neuroimmunologic disorders. Biotech San Diego, United States Series C $100.0M 2024-07-24 $208.7M Insight Partners, Invus, Bristol-Myers Squibb +2 11 to 50 2017
Pathios Therapeutics Pathios Therapeutics develops therapies for autoimmune diseases and cancer. Biotech Oxford, United Kingdom Series B $25.0M 2024-04-18 Innovate UK, Canaan Partners, Bristol-Myers Squibb +2 1 to 10 2017
Capstan Therapeutics Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases. Biotech San Diego, United States Series B $175.0M 2024-03-20 $340.0M RA Capital Management, OrbiMed, Alexandria Venture Investments +2 101 to 250 2021
Accent Therapeutics Accent Therapeutics is a biopharmaceutical company. Biotech Lexington, United States Series C $75.0M 2024-01-23 $178.0M Google Ventures, Mirae Asset Venture Investment, Bristol-Myers Squibb +2 11 to 50 2017
ROME Therapeutics ROME Therapeutics develops therapies for cancer and autoimmune diseases by targeting the repeatome. Biotech Cambridge, United States Series B $72.0M 2023-09-12 $199.0M Andreessen Horowitz, Google Ventures, Alexandria Venture Investments +2 11 to 50 2020
Metagenomi Metagenomi uses metagenomics and machine learning to discover genome editing systems for therapeutics. Artificial intelligence Emeryville, United States Series B $100.0M 2023-01-05 $466.7M RA Capital Management, Bristol-Myers Squibb, Marshall Wace +1 101 to 250 2018
Cardior Pharmaceuticals Cardior Pharmaceuticals develops medicines and therapies to treat and prevent heart disease. Biotech Hanover, Germany Series B $75.3M 2021-08-25 HTGF (High-Tech Gruenderfonds), EQT Life Sciences, Bristol-Myers Squibb +2 11 to 50 2016
Personal Genome Diagnostics Personal Genome Diagnostics analyzes patients' cancer genomes using advanced tools and technologies. Biotech Baltimore, United States Series C $103.0M 2021-02-10 $244.7M New Enterprise Associates, Sands Capital Ventures, Bristol-Myers Squibb +1 101 to 250 2010

Table 1. Bristol-Myers Squibb portfolio companies: the 15 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 20.

Largest rounds

Last 12 months
# Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
1 BigHat Biosciences BigHat Biosciences develops antibody and protein therapeutics using machine learning and automated experimentation. Artificial intelligence San Mateo, United States Series C $75.0M 2026-09-24 $174.3M Andreessen Horowitz, Gaingels, 8VC +2 51 to 100 2019
2 Ratio Therapeutics Ratio Therapeutics develops radiopharmaceuticals to treat solid tumors in clinical trials. Biotech Boston, United States Series C $70.0M 2026-07-31 $160.0M Bristol-Myers Squibb, The Pags Group, Schusterman Family Investments 11 to 50 2021
3 Precede Biosciences Precede Biosciences develops blood-based tests that reveal disease-defining transcriptional biology. Biotech Boston, United States Series B $63.5M 2026-01-12 $140.5M Bristol-Myers Squibb, Lilly Asia Ventures, 5AM Ventures +2 11 to 50 2005
4 Cour Pharmaceuticals Development Cour Pharmaceuticals Development develops nanoparticle technology to reset immune systems in multiple sclerosis patients. Biotech Skokie, United States Series B $50.0M 2026-06-18 $185.5M Alpha Wave Global, Bristol-Myers Squibb, Alpha Wave Ventures +2 51 to 100 2015

Table 2. Bristol-Myers Squibb portfolio companies: the 4 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 RA Capital Management Startup incubator Boston, United States 5 25%
2 Alexandria Venture Investments Venture capital firm Pasadena, United States 4 20%
3 Andreessen Horowitz Venture capital firm Menlo Park, United States 2 10% 1 BigHat Biosciences
4 8VC Venture capital firm Austin, United States 2 10% 1 BigHat Biosciences
5 5AM Ventures Venture capital firm Menlo Park, United States 2 10% 1 Precede Biosciences
6 Roche Venture Fund Corporate venture arm Basel, Switzerland 2 10% 1 Cour Pharmaceuticals Development
7 Google Ventures Corporate venture arm San Francisco, United States 2 10%
8 Blue Owl Private equity firm New York, United States 2 10%
9 Alpha Wave Ventures Corporate venture arm Miami, United States 2 10% 1 Cour Pharmaceuticals Development
10 Innovate UK Entrepreneurship program Swindon, United Kingdom 2 10%
11 The Pags Group Family office Boston, United States 1 5% 1 Ratio Therapeutics
12 Schusterman Family Investments Family office New York, United States 1 5% 1 Ratio Therapeutics
13 Gaingels Syndicate Burlington, United States 1 5% 1 BigHat Biosciences
14 National Institute of Standards and Technology Government investment office Gaithersburg, United States 1 5% 1 BigHat Biosciences
15 Qatar Investment Authority Fund of funds Doha, Qatar 1 5% 1 Precede Biosciences

Table 3. Bristol-Myers Squibb portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Biotech 20 100% $4.1B
Health care 20 100% $4.1B
Software 4 20% $1.3B
Artificial intelligence 2 10% $641.1M

Table 4. Bristol-Myers Squibb portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series A 1 5% $5.2M
Series B 11 55% $75.3M
Series C 8 40% $96.0M

Table 5. Bristol-Myers Squibb portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Countries

CountriesCompaniesShare
United States 16 80%
United Kingdom 2 10%
Switzerland 1 5%
Germany 1 5%

Table 6. Bristol-Myers Squibb portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
San Francisco 3 15%
Boston 2 10%
San Diego 2 10%
San Mateo 1 5%
Wädenswil 1 5%
Cambridge 1 5%
Culver City 1 5%
Skokie 1 5%
Emeryville 1 5%
Lexington 1 5%
South San Francisco 1 5%
Baltimore 1 5%

Table 7. Bristol-Myers Squibb portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
September 2026 1 25% $75.0M
July 2026 1 25% $70.0M
June 2026 1 25% $50.0M
January 2026 1 25% $63.5M

Table 8. Bristol-Myers Squibb portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 4 20% $258.5M
2025 3 15% $231.2M
2024 9 45% $955.0M
2023 2 10% $172.0M
2021 2 10% $178.3M

Table 9. Bristol-Myers Squibb portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2020 to 2022 5 25%
2015 to 2019 13 65%
2010 to 2014 1 5%
Before 2010 1 5%

Table 10. Bristol-Myers Squibb portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 2 10%
11 to 50 10 50%
51 to 100 4 20%
101 to 250 3 15%
251 to 500 1 5%

Table 11. Bristol-Myers Squibb portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many Bristol-Myers Squibb portfolio companies are on the list?
20, in the file dated 16 November 2026. 4 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 20 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Bristol-Myers Squibb portfolio companies: 20 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Portfolio companies by country

Portfolio companies by city

Other venture fund portfolios

Cite: FundingWatcher, 20 startups, 16 November 2026. https://fundingwatcher.com/startups/investor/bristol-myers-squibb/